Tickers

1. Composite Trajectory Verdict

Given ANIK's business model as a manufacturer and commercializer of medical devices with significant R&D investment and recent divestitures, the income statement and cash flow statement carry the most weight for assessing operating performance, while the balance sheet reflects the cumulative impact.

Composite Trajectory: Mixed

The annual income statement shows deteriorating trends: revenue fell 6% to $112.8M in 2025, gross margin compressed 600 basis points to 57%, and loss from continuing operations widened to $10.0M (10-K 2025-12-31, Consolidated Statements of Operations). However, the most recent quarterly periods show improvement: Q2 2026 revenue rose 16% to $32.6M, gross margin expanded to 65% from 51%, and the company reported net income of $3.3M versus a $4.0M loss in Q2 2025 (10-Q 2026-06-30, Consolidated Statements of Operations). Annual operating cash flow improved consecutively to $11.2M in 2025, but H1 2026 operating cash flow deteriorated to -$5.5M from -$0.3M in H1 2025 (10-K 2025-12-31, Consolidated Statements of Cash Flows; 10-Q 2026-06-30, Consolidated Statements of Cash Flows). The balance sheet shows consistent deterioration: equity declined from $154.0M to $137.3M over 18 months, cash fell from $57.5M to $38.4M in H1 2026, and working capital decreased from $90.3M to $77.0M (10-K 2025-12-31, MD&A; 10-Q 2026-06-30, MD&A).

2. Red Flags

• Revenue concentration: J&J MedTech represented 50% of total revenue in 2025 (10-K 2025-12-31, MD&A) and 55% of accounts receivable (10-K 2025-12-31, Note 13).
• Gross margin compression: Annual gross margin fell from 68% (2023) to 63% (2024) to 57% (2025) (10-K 2025-12-31, Consolidated Statements of Operations).
• Widening operating losses: Loss from operations expanded from $5.1M (2024) to $11.1M (2025) (10-K 2025-12-31, Consolidated Statements of Operations).
• Inventory reserves and write-downs: Inventory reserves increased to $4.8M (2025) from $3.9M (2024); provision for inventory was $5.8M in 2025 (10-K 2025-12-31, Note 5; Consolidated Statements of Cash Flows).
• Share repurchases amid losses: $9.5M repurchased in 2025 and $11.0M in H1 2026 while reporting net losses (10-K 2025-12-31, MD&A; 10-Q 2026-06-30, Consolidated Statements of Cash Flows).
• Cash flow reversal: Operating cash flow swung to -$5.5M in H1 2026 from -$0.3M in H1 2025 despite revenue growth (10-Q 2026-06-30, Consolidated Statements of Cash Flows).
• Full valuation allowance on US deferred tax assets: $45.6M valuation allowance against $59.0M gross deferred tax assets (10-K 2025-12-31, Note 17).
• Notes receivable from divestitures: $5.6M outstanding from Arthrosurface sale, dependent on buyer's cash flows (10-K 2025-12-31, Note 3).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Overall Assessment: Annual revenue declined 6% to $112.8M in 2025 from $119.9M in 2024, with OEM channel revenue falling 17% due to lower J&J MedTech pricing and volumes, partially offset by 15% Commercial channel growth (10-K 2025-12-31, MD&A). Gross margin compressed to 57% from 63% (10-K 2025-12-31, Consolidated Statements of Operations). Loss from continuing operations widened to $10.0M from $8.8M (10-K 2025-12-31, Consolidated Statements of Operations). However, the most recent quarterly periods show improvement: Q2 2026 revenue rose 16% to $32.6M, gross margin expanded to 65% from 51%, and the company reported net income of $3.3M versus a $4.0M loss in Q2 2025 (10-Q 2026-06-30, Consolidated Statements of Operations). Year-to-date June 2026 revenue increased 14% to $62.2M, gross margin reached 65% versus 53%, and net loss narrowed to $1.7M from $8.8M (10-Q 2026-06-30, Consolidated Statements of Operations).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

Overall Assessment: Annual operating cash flow improved consecutively: -$1.8M (2023), +$5.4M (2024), +$11.2M (2025) (10-K 2025-12-31, Consolidated Statements of Cash Flows). Investing cash outflows decreased sharply to $0.4M in 2025 from $8.3M in 2024 due to $4.5M proceeds from Parcus sale and $1.3M note receivable collections (10-K 2025-12-31, Consolidated Statements of Cash Flows). Financing cash outflows remained high at $10.6M in 2025 driven by share repurchases (10-K 2025-12-31, Consolidated Statements of Cash Flows). In contrast, the first half of 2026 showed deterioration: operating cash flow was -$5.5M versus -$0.3M in H1 2025, investing cash flow was -$2.5M versus +$1.1M, and financing cash outflows increased to $11.0M from $5.3M (10-Q 2026-06-30, Consolidated Statements of Cash Flows). Cash and equivalents fell to $38.4M at June 30, 2026 from $57.5M at December 31, 2025 (10-Q 2026-06-30, Consolidated Balance Sheets).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Deteriorating

Overall Assessment: Total assets declined from $202.7M (Dec 2024) to $190.3M (Dec 2025) to $183.5M (June 2026) (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Consolidated Balance Sheets). Total equity fell from $154.0M to $143.5M to $137.3M over the same periods (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Consolidated Balance Sheets). Cash and equivalents dropped from $57.5M to $38.4M in the first half of 2026 (10-Q 2026-06-30, Consolidated Balance Sheets). Working capital decreased from $90.3M (Dec 2024) to $80.2M (Dec 2025) to $77.0M (June 2026) (10-K 2025-12-31, MD&A; 10-Q 2026-06-30, MD&A). Inventories rose to $28.6M at June 2026 from $18.8M at Dec 2025, while accounts receivable increased to $29.1M from $23.7M (10-Q 2026-06-30, Consolidated Balance Sheets).

6. Data Gaps

• Standalone quarterly results for Q1 2026, Q3 2025, and Q4 2025 (only YTD and annual provided).
• Quarterly cash flow statements for individual quarters (only YTD provided in 10-Qs).
• Detailed revenue breakdown by product (Monovisc, Orthovisc, Cingal, Integrity, Hyalofast, Tactoset) for quarterly periods.
• Capital expenditure projections for manufacturing expansion.
• Terms and repayment schedule for the $7.0M Arthrosurface Term Note Receivable beyond fair value.
• Post-divestiture OEM agreement terms with J&J MedTech (pricing, volume commitments).
• Quantitative impact of Cingal and Hyalofast FDA approval timelines on revenue and expenses.